{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T06:14:21Z","timestamp":1789798461935,"version":"4.0.1"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,18]]},"DOI":"10.7759\/cureus.116516","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T05:42:49Z","timestamp":1789796569000},"source":"Crossref","is-referenced-by-count":0,"title":["Efficacy, Tolerability, and Safety of Fluoxetine for Panic Disorder in Adults: A Review"],"prefix":"10.7759","author":[{"given":"Haseeb","family":"Mohammad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sehasbir","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inderbir","family":"Singh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD010676.pub2","article-title":"Antidepressants versus placebo for panic disorder in adults","volume":"4","author":"Bighelli I","year":"2018","unstructured":"Bighelli I, Castellazzi M, Cipriani A, et al.. Antidepressants versus placebo for panic disorder in adults. Cochrane Database Syst Rev. 2018, 4:10.1002\/14651858.CD010676.pub2","journal-title":"Cochrane Database Syst Rev"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1176\/ajp.155.11.1570","article-title":"Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group","volume":"155","author":"Michelson D","year":"1998","unstructured":"Michelson D, Lydiard RB, Pollack MH, et al.. Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. Am J Psychiatry. 1998, 155:1570-7. 10.1176\/ajp.155.11.1570","journal-title":"Am J Psychiatry"},{"key":"ref3","article-title":"Generalised Anxiety Disorder and Panic Disorder in Adults: Management. NICE Clinical Guidelines, No. 113","year":"2019","unstructured":"Generalised Anxiety Disorder and Panic Disorder in Adults. Management. NICE Clinical Guidelines, No. 113. National Institute for Health and Care Excellence (NICE), London; 2019."},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.2147\/ndt.s1224","article-title":"Pharmacotherapy of panic disorder","volume":"4","author":"Pull CB","year":"2008","unstructured":"Pull CB, Damsa C. Pharmacotherapy of panic disorder. Neuropsychiatr Dis Treat. 2008, 4:779-95. 10.2147\/ndt.s1224","journal-title":"Neuropsychiatr Dis Treat"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1080\/14737175.2023.2229955","article-title":"Is it possible to prevent relapse in panic disorder?","volume":"23","author":"Freire RC","year":"2023","unstructured":"Freire RC, Nardi AE. Is it possible to prevent relapse in panic disorder?. Expert Rev Neurother. 2023, 23:677-9. 10.1080\/14737175.2023.2229955","journal-title":"Expert Rev Neurother"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.9758\/cpn.2019.17.2.145","article-title":"Pharmacological therapy in panic disorder: current guidelines and novel drugs discovery for treatment-resistant patient","volume":"17","author":"Zulfarina MS","year":"2019","unstructured":"Zulfarina MS, Syarifah-Noratiqah SB, Nazrun SA, Sharif R, Naina-Mohamed I. Pharmacological therapy in panic disorder: current guidelines and novel drugs discovery for treatment-resistant patient. Clin Psychopharmacol Neurosci. 2019, 17:145-54. 10.9758\/cpn.2019.17.2.145","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2832-3-2","article-title":"Fluoxetine: a review on evidence based medicine","volume":"3","author":"Rossi A","year":"2004","unstructured":"Rossi A, Barraco A, Donda P. Fluoxetine: a review on evidence based medicine. Ann Gen Hosp Psychiatry. 2004, 3:2. 10.1186\/1475-2832-3-2","journal-title":"Ann Gen Hosp Psychiatry"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1192\/bjp.179.6.514","article-title":"Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial","volume":"179","author":"Michelson D","year":"2001","unstructured":"Michelson D, Allgulander C, Dantendorfer K, et al.. Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial. Br J Psychiatry. 2001, 179:514-18. 10.1192\/bjp.179.6.514","journal-title":"Br J Psychiatry"},{"key":"ref9","doi-asserted-by":"crossref","DOI":"10.1097\/00004714-198710000-00007","article-title":"An open trial of fluoxetine in the treatment of panic attacks","volume":"7","author":"Gorman JM","year":"1987","unstructured":"Gorman JM, Liebowitz MR, Fyer AJ, et al.. An open trial of fluoxetine in the treatment of panic attacks. J Clin Psychopharmacol. 1987, 7:329-32.","journal-title":"J Clin Psychopharmacol"},{"key":"ref10","article-title":"Fluoxetine in panic disorder: pharmacologic and tritiated platelet imipramine and paroxetine binding study","volume":"20","author":"Pecknold JC","year":"1995","unstructured":"Pecknold JC, Luthe L, Iny L, Ramdoyal D. Fluoxetine in panic disorder: pharmacologic and tritiated platelet imipramine and paroxetine binding study. J Psychiatry Neurosci. 1995, 20:193-8.","journal-title":"J Psychiatry Neurosci"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-025-03893-9","article-title":"Impact of CYP2D6 genotype on fluoxetine exposure and treatment switch in adults and children\/adolescents","volume":"81","author":"Nordby KL","year":"2025","unstructured":"Nordby KL, Faraj P, Molden E, Hole K. Impact of CYP2D6 genotype on fluoxetine exposure and treatment switch in adults and children\/adolescents. Eur J Clin Pharmacol. 2025, 81:1623-32. 10.1007\/s00228-025-03893-9","journal-title":"Eur J Clin Pharmacol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1021\/ja048114o","article-title":"Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids","volume":"126","author":"Childs SL","year":"2004","unstructured":"Childs SL, Chyall LJ, Dunlap JT, Smolenskaya VN, Stahly BC, Stahly GP. Crystal engineering approach to forming cocrystals of amine hydrochlorides with organic acids. Molecular complexes of fluoxetine hydrochloride with benzoic, succinic, and fumaric acids. J Am Chem Soc. 2004, 126:13335-42. 10.1021\/ja048114o","journal-title":"J Am Chem Soc"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics18010041","article-title":"Pharmacogenomics of CYP2D6, CYP2C19, CYP2C9, and clinical determinants of fluoxetine-norfluoxetine pharmacokinetics in real-world clinical conditions","volume":"18","author":"de la Cruz CG","year":"2025","unstructured":"de la Cruz CG, Thomas L, Mata-Mart\u00edn C, Gonz\u00e1lez I, LLerena A, Pe\u00f1as-Lled\u00f3 EM. Pharmacogenomics of CYP2D6, CYP2C19, CYP2C9, and clinical determinants of fluoxetine-norfluoxetine pharmacokinetics in real-world clinical conditions. Pharmaceutics. 2025, 18:10.3390\/pharmaceutics18010041","journal-title":"Pharmaceutics"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3109\/10837450.2012.696270","article-title":"Hydrochloride salt co-crystals: preparation, characterization and physicochemical studies","volume":"18","author":"Parmar VK","year":"2013","unstructured":"Parmar VK, Shah SA. Hydrochloride salt co-crystals: preparation, characterization and physicochemical studies. Pharm Dev Technol. 2013, 18:443-53. 10.3109\/10837450.2012.696270","journal-title":"Pharm Dev Technol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.4c00085","article-title":"Potentiation of brain bioavailability using thermoreversible cubosomal formulation","volume":"21","author":"Jain H","year":"2024","unstructured":"Jain H, Prabhakar B, Shende PK. Potentiation of brain bioavailability using thermoreversible cubosomal formulation. Mol Pharm. 2024, 21:2534-43. 10.1021\/acs.molpharmaceut.4c00085","journal-title":"Mol Pharm"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1016\/j.exger.2024.112533","article-title":"PEGylated chitosan nanoparticles of fluoxetine enhance cognitive performance and hippocampal brain derived neurotrophic factor levels in a rat model of local demyelination","volume":"195","author":"Dadkhah M","year":"2024","unstructured":"Dadkhah M, Afshari S, Samizadegan T, Shirmard LR, Barin S. PEGylated chitosan nanoparticles of fluoxetine enhance cognitive performance and hippocampal brain derived neurotrophic factor levels in a rat model of local demyelination. Exp Gerontol. 2024, 195:10.1016\/j.exger.2024.112533","journal-title":"Exp Gerontol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/YIC.0b013e32835a5d2e","article-title":"Newer antidepressants and panic disorder: a meta-analysis","volume":"28","author":"Andrisano C","year":"2013","unstructured":"Andrisano C, Chiesa A, Serretti A. Newer antidepressants and panic disorder: a meta-analysis. Int Clin Psychopharmacol. 2013, 28:33-45. 10.1097\/YIC.0b013e32835a5d2e","journal-title":"Int Clin Psychopharmacol"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajp.2021.102664","article-title":"Comparative efficacy and acceptability of antidepressants and benzodiazepines for the treatment of panic disorder: a systematic review and network meta-analysis","volume":"60","author":"Du Y","year":"2021","unstructured":"Du Y, Du B, Diao Y, et al.. Comparative efficacy and acceptability of antidepressants and benzodiazepines for the treatment of panic disorder: a systematic review and network meta-analysis. Asian J Psychiatr. 2021, 60:10.1016\/j.ajp.2021.102664","journal-title":"Asian J Psychiatr"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1136\/bmj-2021-066084","article-title":"Drug treatment for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials","volume":"376","author":"Chawla N","year":"2022","unstructured":"Chawla N, Anothaisintawee T, Charoenrungrueangchai K, Thaipisuttikul P, McKay GJ, Attia J, Thakkinstian A. Drug treatment for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials. BMJ. 2022, 376:10.1136\/bmj-2021-066084","journal-title":"BMJ"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1002\/14651858.CD012729.pub3","article-title":"Pharmacological treatments in panic disorder in adults: a network meta-analysis","volume":"11","author":"Guaiana G","year":"2023","unstructured":"Guaiana G, Meader N, Barbui C, et al.. Pharmacological treatments in panic disorder in adults: a network meta-analysis. Cochrane Database Syst Rev. 2023, 11:10.1002\/14651858.CD012729.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/pl00014164","article-title":"Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group","volume":"249","author":"Tiller JW","year":"1999","unstructured":"Tiller JW, Bouwer C, Behnke K. Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group. Eur Arch Psychiatry Clin Neurosci. 1999, 249:7-10. 10.1007\/pl00014164","journal-title":"Eur Arch Psychiatry Clin Neurosci"},{"key":"ref22","doi-asserted-by":"crossref","DOI":"10.1590\/S0100-879X2001001000010","article-title":"Mirtazapine versus fluoxetine in the treatment of panic disorder","volume":"34","author":"Ribeiro L","year":"2001","unstructured":"Ribeiro L, Busnello JV, Kauer-Sant'Anna M, Madruga M, Quevedo J, Busnello EA, Kapczinski F. Mirtazapine versus fluoxetine in the treatment of panic disorder. Braz J Med Biol Res. 2001, 34:1303-7.","journal-title":"Braz J Med Biol Res"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","article-title":"The assessment of anxiety states by rating","volume":"32","author":"Hamilton M","year":"1959","unstructured":"Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959, 32:50-5. 10.1111\/j.2044-8341.1959.tb00467.x","journal-title":"Br J Med Psychol"},{"key":"ref24","article-title":"The Anxiety Disease","author":"Sheehan DV","year":"1983","unstructured":"Sheehan DV. The Anxiety Disease. Charles Scribner and Sons, New York; 1983."},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.4088\/jcp.v60n0505","article-title":"Once-weekly dosing of fluoxetine in the maintenance of remission in panic disorder","volume":"60","author":"Emmanuel NP","year":"1999","unstructured":"Emmanuel NP, Ware MR, Brawman-Mintzer O, Ballenger JC, Lydiard RB. Once-weekly dosing of fluoxetine in the maintenance of remission in panic disorder. J Clin Psychiatry. 1999, 60:299-301. 10.4088\/jcp.v60n0505","journal-title":"J Clin Psychiatry"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0178617","article-title":"Is the efficacy of antidepressants in panic disorder mediated by adverse events? A mediational analysis","volume":"12","author":"Bighelli I","year":"2017","unstructured":"Bighelli I, Borghesani A, Barbui C. Is the efficacy of antidepressants in panic disorder mediated by adverse events? A mediational analysis. PLoS One. 2017, 12:10.1371\/journal.pone.0178617","journal-title":"PLoS One"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3238\/arztebl.2019.0355","article-title":"Antidepressant withdrawal and rebound phenomena","volume":"116","author":"Henssler J","year":"2019","unstructured":"Henssler J, Heinz A, Brandt L, Bschor T. Antidepressant withdrawal and rebound phenomena. Dtsch Arztebl Int. 2019, 116:355-61. 10.3238\/arztebl.2019.0355","journal-title":"Dtsch Arztebl Int"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2903","article-title":"Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants","volume":"114","author":"Bousman CA","year":"2023","unstructured":"Bousman CA, Stevenson JM, Ramsey LB, et al.. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A genotypes and serotonin reuptake inhibitor antidepressants. Clin Pharmacol Ther. 2023, 114:51-68. 10.1002\/cpt.2903","journal-title":"Clin Pharmacol Ther"},{"key":"ref29","article-title":"Fluoxetine","author":"Sohel AJ","year":"2026","unstructured":"Sohel AJ, Shutter MC, Patel P, Molla M. Fluoxetine. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2026."},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0447.2008.01157.x","article-title":"Is a combined therapy more effective than either CBT or SSRI alone? Results of a multicenter trial on panic disorder with or without agoraphobia","volume":"117","author":"van Apeldoorn FJ","year":"2008","unstructured":"van Apeldoorn FJ, van Hout WJ, Mersch PP, et al.. Is a combined therapy more effective than either CBT or SSRI alone? Results of a multicenter trial on panic disorder with or without agoraphobia. Acta Psychiatr Scand. 2008, 117:260-70. 10.1111\/j.1600-0447.2008.01157.x","journal-title":"Acta Psychiatr Scand"},{"key":"ref31","doi-asserted-by":"publisher","DOI":"10.7189\/jogh.16.04090","article-title":"Innovative virtual reality exposure therapy for anxiety and posttraumatic stress disorder: a meta-analysis of randomised controlled trials","volume":"16","author":"Chang YC","year":"2026","unstructured":"Chang YC, Arifin H, Hung TM, et al.. Innovative virtual reality exposure therapy for anxiety and posttraumatic stress disorder: a meta-analysis of randomised controlled trials. J Glob Health. 2026, 16:04090. 10.7189\/jogh.16.04090","journal-title":"J Glob Health"},{"key":"ref32","doi-asserted-by":"publisher","DOI":"10.1016\/j.brat.2021.103984","article-title":"Pilot randomized trial of self-guided virtual reality exposure therapy for social anxiety disorder","volume":"147","author":"Zainal NH","year":"2021","unstructured":"Zainal NH, Chan WW, Saxena AP, Taylor CB, Newman MG. Pilot randomized trial of self-guided virtual reality exposure therapy for social anxiety disorder. Behav Res Ther. 2021, 147:103984. 10.1016\/j.brat.2021.103984","journal-title":"Behav Res Ther"},{"key":"ref33","doi-asserted-by":"publisher","DOI":"10.1016\/j.comppsych.2023.152447","article-title":"Personalized virtual reality exposure for panic disorder and agoraphobia: a preliminary neurophysiological study","volume":"129","author":"Jung HW","year":"2024","unstructured":"Jung HW, Jang KW, Nam S, et al.. Personalized virtual reality exposure for panic disorder and agoraphobia: a preliminary neurophysiological study. Compr Psychiatry. 2024, 129:10.1016\/j.comppsych.2023.152447","journal-title":"Compr Psychiatry"},{"key":"ref34","doi-asserted-by":"publisher","DOI":"10.1037\/0033-295X.84.2.191","article-title":"Self-efficacy: toward a unifying theory of behavioral change","volume":"84","author":"Bandura A","year":"1977","unstructured":"Bandura A. Self-efficacy: toward a unifying theory of behavioral change. Psychol Rev. 1977, 84:191-215. 10.1037\/0033-295X.84.2.191","journal-title":"Psychol Rev"},{"key":"ref35","doi-asserted-by":"publisher","DOI":"10.1016\/j.brat.2013.09.001","article-title":"Mechanisms of change in cognitive behavioral therapy for panic disorder: the unique effects of self-efficacy and anxiety sensitivity","volume":"51","author":"Gallagher MW","year":"2013","unstructured":"Gallagher MW, Payne LA, White KS, Shear KM, Woods SW, Gorman JM, Barlow DH. Mechanisms of change in cognitive behavioral therapy for panic disorder: the unique effects of self-efficacy and anxiety sensitivity. Behav Res Ther. 2013, 51:767-77. 10.1016\/j.brat.2013.09.001","journal-title":"Behav Res Ther"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/533239-efficacy-tolerability-and-safety-of-fluoxetine-for-panic-disorder-in-adults-a-review","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T05:42:50Z","timestamp":1789796570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/533239-efficacy-tolerability-and-safety-of-fluoxetine-for-panic-disorder-in-adults-a-review"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,18]]},"references-count":35,"URL":"https:\/\/doi.org\/10.7759\/cureus.116516","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9,18]]}}}